Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of anal high-grade squamous intraepithelial lesions among renal transplant recipients compared with immunocompetent controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Charlotte G Hannibal
  • Kirsten Frederiksen
  • Russell Vang
  • Robert J Kurman
  • Susanne K Kjaer
Vis graf over relationer

Population-based evidence regarding risk of ovarian cancer after a borderline ovarian tumor (BOT) is sparse. We aimed to examine the incidence of specific types of ovarian cancer in women with serous or mucinous BOTs in a nationwide cohort study with up to 36 years of follow-up. Using the nationwide Danish Pathology Data Bank, we identified 4,281 women with a BOT (2,058 serous BOTs and 2,223 mucinous BOTs) in Denmark during 1978-2012. We computed standardized incidence ratios (SIRs) to compare the incidence of ovarian cancer among women with BOTs compared to general population rates. We found that a serous BOT was especially and strongly associated with subsequent serous ovarian cancer (SIR = 9.2; 95% CI: 6.8-12.2), and that a mucinous BOT was strongly related to mucinous ovarian cancer (SIR = 18.6; 95% CI: 10.8-29.8). The SIRs remained elevated ≥10 years after a serous BOT and up to 5-9 years after a mucinous BOT. The increased incidence of serous ovarian cancer in women with a serous BOT was mostly pronounced in women <50 years at the serous BOT diagnosis. In conclusion, women with a serous BOT experience long-term increased incidence of serous ovarian cancer, and women with a mucinous BOT have long-term elevated incidence of mucinous ovarian cancer compared to the general population. This is the first population-based study to show compelling evidence of the histo-specific increased risk of ovarian cancer following specific types of BOTs. Thus, these results are supportive of the hypothesis that BOTs may be precursor lesions to carcinomas of the corresponding histologic type.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind147
Udgave nummer4
Sider (fra-til)990-995
Antal sider6
ISSN0020-7136
DOI
StatusUdgivet - 15 aug. 2020

Bibliografisk note

© 2020 UICC.

ID: 61594120